Reasons for lack of appropriate receipt of primary Pneumocystis jiroveci pneumonia prophylaxis among HIV-infected persons receiving treatment in the United States: 1994-2003

Clinical Infectious Diseases

Volumn 44, Issue 6, 2007, Pages 879-883

  Teshale, Eyasu H ^a,b   Hanson, Debra L ^c   Wolfe, Mitchell I ^c   Brooks, John T ^c   Kaplan, Jonathan E ^c   Bort, Zuleika ^c   Sullivan, Patrick S ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; ETHNIC GROUP; FEMALE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; UNITED STATES; VIRUS LOAD;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; COMORBIDITY; FEMALE; FUNGAL VACCINES; HEALTH CARE SURVEYS; HUMANS; INCIDENCE; MALE; MULTIVARIATE ANALYSIS; PNEUMOCYSTIS JIROVECI; PNEUMONIA, PNEUMOCYSTIS; PRIMARY PREVENTION; PROBABILITY; QUALITY OF HEALTH CARE; RISK ASSESSMENT; UNITED STATES; VACCINATION;

EID: 33847632210     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/511862     Document Type: Article

References (13)

1. Hay JW, Osmond DH, Jacobson MA. Projecting the medical cost of AIDS and ARC in the United States. J Acquir Immune Defic Syndr 1987; 1:466-85.
2. Fischel MA, Dickenson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988; 259:1185-9.
3. Bozette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three anti-pneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:693-9.
4. Kaplan JE, Hanson D, Dworkin M, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30:55-14.
5. US Department of Health and Human Services. Healthy People 2010: understanding and improving health. 2nd ed. 2000. Available at: http: //www.healthypeople.gov/Publications/. Accessed 10 November 2006.
6. Centers for Disease Control and Prevention. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with hu-man immunodeficiency virus. Morb Mortal Wkly Rep 1989;38(Suppl 5):1-9.
7. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Clin Infect Dis 1995;21(Suppl 1):S12-31.
8. US Public Health Service (USPHS), Infectious Diseases Society of America (IDSA), USPHS/IDSA Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clin Trials 2001; 2:493-554.
9. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med 1999; 340:1301-6.
10. Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet 1999; 353:1293-8.
11. Yangco BF, VonBargen JC, Moorman AC, Holmberg SD. Discontinuation of chemoprophylaxis for Pneumocystis carinii pneumonia in patients with HIV infection. Ann Intern Med 2000; 132:201-5.
12. Schneider MM, Borleffs JC, Stolk RP, Jaspers CA, Hoepelman AI. Discontinuation of Pneumocystis carinii pneumonia prophylaxis in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 1999; 353:201-3.
13. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in United States. JAMA 1992; 267:1798-1805.